Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage.
In summary, evidence is presented associating typically asymptomatic and reversible elevations of serum transaminase values with high daily dosages of naltrexone. Statistical significance was found only between placebo and the 300 mg dosage. Subjects aged 40 years and over were significantly more likely to develop this finding than younger subjects. All subjects with significant elevations of transaminase values in these studies took daily naltrexone dosages higher than recommended for opioid addiction. The daily dosage of naltrexone recommended for opioid addiction did not cause abnormalities of serum transaminase values in these studies.
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood*; D001219:Aspartate Aminotransferases / Q000097:blood*; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy* / Q000201:enzymology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008111:Liver Function Tests; D008875:Middle Aged; D009271:Naltrexone / Q000627:therapeutic use*; D009765:Obesity / Q000097:blood / Q000188:drug therapy*; D011897:Random Allocation
D009271:Naltrexone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase